Intranasal salbutamol instillation in asthma attack

Natan Weksler, S. Brill, A. Tarnapolski, G. M. Gurman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Beta-two sympathomimetic drugs are the treatment of choice for asthmatic attack. Their main effect is to dilate the bronchi by a direct action on beta-two adrenoreceptors on the smooth muscle, and also by mediator release inhibition from mast cells. Salbutamol is widely used in the treatment of bronchial asthma, and is usually administered either by inhalation, orally, or parenterally. The nasal route seems to afford an effective way to administer medications, since the nasal mucosa has a relatively large surface area, and there is no gastrointestinal-hepatic first pass-effect, thus avoiding extensive loss of the administered drug. We describe herein the use of nasal salbutamol in 3 patients with severe asthma attacks who were refractory to conventional therapy, with favorable responses and without significant undesirable effects.

Original languageEnglish
Pages (from-to)686-688
Number of pages3
JournalAmerican Journal of Emergency Medicine
Issue number7
StatePublished - 1 Jan 1999
Externally publishedYes


  • Asthma
  • Nasal route
  • Salbutamol

ASJC Scopus subject areas

  • Emergency Medicine


Dive into the research topics of 'Intranasal salbutamol instillation in asthma attack'. Together they form a unique fingerprint.

Cite this